Navigation Links
Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
Date:10/1/2008

24, 30 and 36. Except for the month 12 and final month 36 looks when the database will be fully locked, interim evaluations will be based on unaudited data. The last patient was enrolled in this study at the end of February 2008.

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India, with a combined total enrollment of 956 patients.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, which Alimera is studying as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera has exercised its option to acquire a license with respect to one of these classes of NADPH oxidase inhibitors.

For more information on Alimera Sciences, visit http://www.alimerasciences.com.


'/>"/>
SOURCE Alimera Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
2. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
3. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
4. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
5. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
8. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
11. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Ameritox, the nation,s leader in pain medication monitoring, ... become part of its Urine Drug Monitoring (UDM) ... improve the clinical outcomes for injured workers. ... in the workers, compensation industry, has used UDM ... strategy for several years. By establishing a comprehensive ...
(Date:5/23/2013)... TEL AVIV, Israel , May 23, 2013 ... of BrainTech Israel 2013 , Israel,s ... take place on October 14 th -15 th in ... 2 nd most innovative city in the world by ... the "Start-up Nation." BrainTech Israel 2013 will showcase ...
(Date:5/23/2013)... 23, 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... of David A. Ramsay ... recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and his ... in our commercial group for the last four ...
Breaking Medicine Technology:Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
(Date:5/23/2013)... May 23, 2013 Dr. Damon Huffman of ... suffer from gum disease a revolutionary new treatment method with ... millions of Americans who suffer from periodontal disease, and many ... treatment. Dr. Huffman is hoping that LANAP will encourage ... treatment. , Periodontal disease can cause gums ...
(Date:5/23/2013)... Vinci surgical robot maker Intuitive Surgical defeated negligent training ... according to Bloomberg.* The Rottenstein Law Group LLP, which ... disappointment in the ruling but encourages those looking to ... verdict as representative of all da Vinci lawsuits. , ... Surgical Inc.; 09-2-03136-5, Superior Court, Port Orchard, Wash.) focused ...
(Date:5/23/2013)... Plano, TX (PRWEB) May 23, 2013 ... the Marketplace , Chaplains have been a part of ... this Memorial Day, like those preceding it, these men ... service to the United States of America. As ... trend of their migration to the workplace chaplaincy world. ...
(Date:5/23/2013)... May 23, 2013 Live ... contemporary services, provides the best business lead solution ... Its Call center Management solution features Free Web ... Call Limitation, Do-Not-Call Maintenance and "Automatic Transfer Retry". ... comprehensive campaign delivery and management system. , Its ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New ... Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , dedicated ... who are considering filing lawsuits. , The painkiller ... liver damage, according to a 2009 report from the ... communication,” the FDA warned consumers against using more than ...
Breaking Medicine News(10 mins):Health News:Humble, TX Dentist, Dr. Damon Huffman Now Offers Laser Periodontal Disease Treatment to Gum Disease Patients 2Health News:Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2
... The Children,s Hospital of Philadelphia contributed important expertise to ... brain tumor typically found in children. The large multicenter ... holds intriguing clues to gene changes on signaling pathways ... The most common cancerous brain tumor in children, medulloblastoma ...
... , Orange, Calif., Dec.16, 2010 The American Heart Association ... of care for heart failure patients. The Get With ... UC Irvine Medical Center has achieved at least 85 percent ... heart failure patients. The medical center,s compliance rate was ...
... By Dennis Thompson HealthDay Reporter , THURSDAY, ... supplements for centuries to cure all manner of ills and ... the use of such plants as St. John,s wort and ... unknown. But the federal government is spending millions of ...
... a new report that bucks the concerns raised by the ... Health (BUSPH) (sph.bu.edu) researcher concludes that electronic cigarettes are much ... against tobacco-related diseases and death. The review, which ... the Journal of Public Health Policy , is the ...
... treatment of chronic pain from the patient,s perspective, there has ... pain. In a study in the November ... from the Regenstrief Institute, the Indiana University School of Medicine, ... Medical Center report that chronic pain takes a toll on ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... advisers urged the agency to take a new look at ... that include mercury. The FDA had ruled in 2009 ... "We need to see where the science is and ...
Cached Medicine News:Health News:CHOP experts collaborate in gene survey of childhood brain cancer; intriguing clues found 2Health News:UC Irvine Medical Center recognized for heart failure program 2Health News:U.S. Spending Millions to See if Herbs Truly Work 2Health News:U.S. Spending Millions to See if Herbs Truly Work 3Health News:Evidence suggests e-cigs safer than cigarettes, researcher claims 2Health News:It's a pain to take care of pain 2Health News:It's a pain to take care of pain 3Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 2Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 3
... Varicella-Zoster (VZ) test system ... and semi-quantitative detection of VZ ... by the indirect fluorescent antibody ... determine or confirm a recent ...
... Biotech Captia™ Varicella-Zoster Virus (VZV) ... is intended for the detection ... virus in human serum as ... of primary infection or reactivation. ...
... Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked Immunosorbent ... and quantitative determination of IgG antibody to ... may be used for the determination of ... may be used to demonstrate seroconversion or ...
ELISA kit for Varicella-zoster IgM....
Medicine Products: